Barclays raises West Pharmaceutical target to USD 440 for West Pharmaceutical stock
Published on 10/08/2026 at 11:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical stock was trading at EUR 324.85 at Lang & Schwarz on October 8, 2026 at 11:47 a.m. CEST, down 0.76 percent versus the prior close of EUR 327.35. Markets Insider reported on October 7, 2026 that Barclays analyst Luke Sergott raised the target from USD 400.00 to USD 440.00 while keeping an Overweight rating.
Barclays raises the valuation bar
The new target is 10.25 percent above the Lang & Schwarz price when compared across currencies only through the underlying USD listing, so the euro quote remains the article's reference price. Barclays made the change as part of a third-quarter earnings preview and described the setup for life science and diagnostic stocks as extremely tough because valuations already reflect material upside in estimates.
The target change gives investors a concrete benchmark before West Pharmaceutical's next reported results. It also places greater emphasis on whether the company can sustain the operating progress shown in the second quarter.
Second-quarter growth sets the test
According to Simply Wall St, West Pharmaceutical reported second-quarter 2026 revenue of USD 872.30 million, up 13.80 percent from the second quarter of 2025, and net income of USD 154.00 million, up 17.00 percent. The finance statement data put diluted earnings per share at USD 2.15 for the quarter, while the revenue and net-income figures provide the clearer operating comparison.
Yahoo Finance also reported that second-quarter revenue exceeded analyst expectations by 3.50 percent. The combination of double-digit revenue growth and a higher target explains why the upcoming report carries more weight than the modest euro-price decline on October 8.
Results date sets the next checkpoint
MarketBeat lists October 22, 2026 as the date for West Pharmaceutical's third-quarter 2026 earnings report before the market opens. Its estimate calls for revenue of USD 826.77 million, making the reported figure a future consensus reference rather than an actual result.
Stock remains below the target
West Pharmaceutical was trading at EUR 324.85 at Lang & Schwarz on October 8, 2026 at 11:47 a.m. CEST, down 0.76 percent versus the prior close of EUR 327.35. The primary listing is on the NYSE, where the finance quote showed USD 366.48 on October 7, 2026, with a 52-week range of USD 223.83 to USD 386.00 and market capitalization of USD 25.8 billion.
The further course of trading is shown by the continuously updated real-time quote of West Pharmaceutical stock.
West Pharmaceutical stock facts
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9553061055
- Ticker: WST
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 8, 2026 at 11:47 a.m. CEST: EUR 324.85
- Change versus prior close: minus 0.76 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 327.35
- Market capitalization: USD 25.8 billion as of October 7, 2026
- 52-week range: USD 223.83-386.00 as of October 7, 2026
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Next earnings date: October 22, 2026
